参考文献
1: Padhy D, Rao A. Bimatoprost (0.03%)-induced accommodative spasm and
pseudomyopia. BMJ Case Rep. 2015 Nov 23;2015. pii: bcr2015211820. doi:
10.1136/bcr-2015-211820. PubMed PMID: 26598527.
2: Oddone F, Rossetti L, Tanga L, Berardo F, Ferrazza M, Michelessi M, Roberti G,
Manni G, Centofanti M. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on
Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or
Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical
Trial. PLoS One. 2015 Oct 20;10(10):e0140601. doi: 10.1371/journal.pone.0140601.
eCollection 2015. PubMed PMID: 26484767; PubMed Central PMCID: PMC4615626.
3: Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E,
Krauss AH. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric
Oxide-Donating Bimatoprost in Preclinical Models. Invest Ophthalmol Vis Sci. 2015
Oct 1;56(11):6558-64. doi: 10.1167/iovs.15-17190. PubMed PMID: 26457541.
4: Karslioğlu MZ, Hoşal MB, Tekeli O. Periocular changes in topical bimatoprost
and latanoprost use. Turk J Med Sci. 2015;45(4):925-30. PubMed PMID: 26422869.
5: Cordeiro MF, Goldberg I, Schiffman R, Bernstein P, Bejanian M. Efficacy of a
preservative-free formulation of fixed-combination bimatoprost and timolol
(Ganfort PF) in treatment-naïve patients vs previously treated patients. Clin
Ophthalmol. 2015 Aug 31;9:1605-11. doi: 10.2147/OPTH.S84163. eCollection 2015.
PubMed PMID: 26357461; PubMed Central PMCID: PMC4560512.
6: Maruyama Y, Ikeda Y, Mori K, Ueno M, Yoshikawa H, Kinoshita S. Comparison
between bimatoprost and latanoprost-timolol fixed combination for efficacy and
safety after switching patients from latanoprost. Clin Ophthalmol. 2015 Aug
7;9:1429-36. doi: 10.2147/OPTH.S87613. eCollection 2015. PubMed PMID: 26300624;
PubMed Central PMCID: PMC4535543.
7: Wirta D, Pariser DM, Yoelin SG, Arase S, McMichael A, Weng E, Mao C, Demos G,
Vandenburgh A. Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A
Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials. J Clin
Aesthet Dermatol. 2015 Jul;8(7):17-29. PubMed PMID: 26203317; PubMed Central
PMCID: PMC4509582.
8: Kook MS, Simonyi S, Sohn YH, Kim CY, Park KH. Bimatoprost 0.01 % for
previously treated patients with open-angle glaucoma or ocular hypertension in
the Korean clinical setting. Jpn J Ophthalmol. 2015 Sep;59(5):325-34. doi:
10.1007/s10384-015-0392-2. Epub 2015 Jul 23. PubMed PMID: 26202440.
9: Wirta D, Baumann L, Bruce S, Ahluwalia G, Weng E, Daniels S. Safety and
Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects. J Clin
Aesthet Dermatol. 2015 Apr;8(4):11-20. PubMed PMID: 26060513; PubMed Central
PMCID: PMC4456802.
10: Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
Plast Surg Nurs. 2015 Apr-Jun;35(2):82-91. doi: 10.1097/PSN.0000000000000097.
PubMed PMID: 26020474.
11: Schnober D, Hubatsch DA, Scherzer ML. Efficacy and safety of
fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from
bimatoprost 0.03%/timolol 0.5% combination therapy. Clin Ophthalmol. 2015 May
7;9:825-32. doi: 10.2147/OPTH.S80880. eCollection 2015. PubMed PMID: 26005326;
PubMed Central PMCID: PMC4428365.
12: Fang Y, Ling Z, Sun X. Fixed-combination treatments for intraocular
hypertension in Chinese patients - focus on bimatoprost-timolol. Drug Des Devel
Ther. 2015 May 13;9:2617-25. doi: 10.2147/DDDT.S80338. eCollection 2015. Review.
PubMed PMID: 25999695; PubMed Central PMCID: PMC4435054.
13: Sarnoff DS, Gotkin RH. Bimatoprost-induced chemical blepharoplasty. J Drugs
Dermatol. 2015 May;14(5):472-7. PubMed PMID: 25942665.
14: Jha AK, Sinha R, Prasad S, Nandan N. Bimatoprost in periorbital vitiligo: a
ray of hope or dilemma. J Eur Acad Dermatol Venereol. 2015 May 4. doi:
10.1111/jdv.13176. [Epub ahead of print] PubMed PMID: 25941113.
15: Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus Mometasone
Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study. Dermatology.
2015;230(4):308-13. doi: 10.1159/000371416. Epub 2015 Mar 4. PubMed PMID:
25765294.
16: Rossetti L, Sacchi M, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M,
Boehm A, Vorwerk C, Goldblum D, Fogagnolo P. Comparison of the effects of
bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood
and ocular perfusion pressures: the results of a randomized trial. BMC
Ophthalmol. 2015 Jan 22;15:7. doi: 10.1186/1471-2415-15-7. PubMed PMID: 25613811;
PubMed Central PMCID: PMC4320581.
17: Prévost S, Thai K, Schützenmeister N, Coulthard G, Erb W, Aggarwal VK.
Synthesis of prostaglandin analogues, latanoprost and bimatoprost, using
organocatalysis via a key bicyclic enal intermediate. Org Lett. 2015 Feb
6;17(3):504-7. doi: 10.1021/ol503520f. Epub 2015 Jan 12. PubMed PMID: 25582321.
18: Natt NK, Gupta A, Singh G, Singh T. A pharmacoeconomic analysis to determine
the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine
0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Indian J Ophthalmol. 2014 Dec;62(12):1136-40. doi: 10.4103/0301-4738.149134.
PubMed PMID: 25579357; PubMed Central PMCID: PMC4313493.
19: García-López A, Paczka JA, Jiménez-Román J, Hartleben C. Efficacy and
tolerability of fixed-combination bimatoprost/timolol versus fixed-combination
dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or
ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol.
2014 Dec 19;14:161. doi: 10.1186/1471-2415-14-161. PubMed PMID: 25527295; PubMed
Central PMCID: PMC4298061.
20: Park KH, Simonyi S, Kim CY, Sohn YH, Kook MS. Bimatoprost 0.01% in
treatment-naïve patients with open-angle glaucoma or ocular hypertension: an
observational study in the Korean clinical setting. BMC Ophthalmol. 2014 Dec
17;14:160. doi: 10.1186/1471-2415-14-160. PubMed PMID: 25519810; PubMed Central
PMCID: PMC4289567.
